-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Spero Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2015 to Q3 2025.
- Spero Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $0.000, a 100% decline year-over-year.
- Spero Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $0.000, a 100% decline from 2023.
- Spero Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $2.6M.
- Spero Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $0.000.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)